Palladio Biosciences
Palladio Biosciences is a private, clinical-stage biopharmaceutical company founded in 2015 and based in Horsham, Pennsylvania, developing therapeutics for orphan diseases of the kidney.
- Company typePrivate
- Founded2015
- HeadquartersHorsham, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Palladio Biosciences firmographics
Firmographics- Name
- Palladio Biosciences
- Website
- https://palladiobio.com
- Company type
- Private
- Founded year
- 2015
- Headcount range
- 1–10 employees
- Short description
- Palladio Biosciences is a private, clinical-stage biopharmaceutical company founded in 2015 and based in Horsham, Pennsylvania, developing therapeutics for orphan diseases of the kidney.
- Ownership category
- akta.pro rank
Palladio Biosciences industry classification
Industry- Product category
- Rare Disease Therapeutics
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Palladio Biosciences is headquartered
LocationHeadquarters
- HQ city
- Horsham
- HQ country
- United States
- HQ region
- North America
Markets served
Palladio Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Palladio Biosciences product offering
Product offeringCore offering
Palladio Biosciences is a clinical-stage biopharmaceutical company developing transformative medicines for orphan diseases of the kidney. The company focuses on discovering and advancing therapeutic candidates targeting rare renal conditions with high unmet medical need. Its lead program is centered on lixivaptan, a vasopressin V2 receptor antagonist being developed for autosomal dominant polycystic kidney disease (ADPKD).
Differentiator
Problem solved
Functional benefit
Products and services
- Lixivaptan
Companies that use Palladio Biosciences
Customer profileIdeal customer profiles2 records
Palladio Biosciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Palladio Biosciences competitors and assessment
Company assessmentDirect peers
- Otsuka Pharmaceutical: Otsuka markets tolvaptan (JYNARQUE/Samsca) for ADPKD and hyponatremia, the established standard-of-care in the same orphan kidney indication Palladio targets. It is the most direct competitive comparable for clinical and commercial positioning.
- Reata Pharmaceuticals: Reata developed bardoxolone methyl for chronic kidney disease and Alport syndrome, and was acquired by Biogen. It is a directly comparable orphan renal disease drug developer with similar clinical, regulatory, and partnership dynamics.
- XORTX Therapeutics: XORTX is a small clinical-stage biotech developing therapies for orphan kidney diseases including ADPKD. It is comparable as a similarly sized, focused orphan renal player with overlapping clinical milestones and investor base dynamics.
Broad incumbents
- Galapagos NV: Galapagos has had programs in ADPKD (e.g., GLPG2737) and broader renal/fibrotic disease indications. It is a broader European biotech incumbent with overlapping renal pipeline targets.
- Vertex Pharmaceuticals: Vertex operates in rare disease drug development with growing interest in kidney targets (e.g., APOL1-mediated kidney disease). It is comparable as a high-value rare-disease innovator with potential strategic interest in orphan renal assets.
- Sanofi: Sanofi has historic renal disease programs (e.g., polycystic kidney disease) and a large rare-disease franchise through Genzyme. It is comparable as a potential strategic acquirer with adjacent kidney and rare-disease capabilities.
Emerging players
- Eloxx Pharmaceuticals: Eloxx develops therapies for rare genetic diseases with renal manifestations (e.g., Alport syndrome). It is comparable as a small-cap emerging player pursuing orphan renal and genetic disease indications.
Market position
Customer concentration
Palladio Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Palladio Biosciences leadership team
Management profileNumber of profiles
Profiles3 records
Palladio Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Palladio Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Palladio Biosciences
What does Palladio Biosciences do?
Palladio Biosciences is a clinical-stage biopharmaceutical company developing transformative medicines for orphan diseases of the kidney. The company focuses on discovering and advancing therapeutic candidates targeting rare renal conditions with high unmet medical need. Its lead program is centered on lixivaptan, a vasopressin V2 receptor antagonist being developed for autosomal dominant polycystic kidney disease (ADPKD).
When was Palladio Biosciences founded?
Palladio Biosciences was founded in 2015. It employs 1 to 10 people.
Where is Palladio Biosciences based?
Palladio Biosciences is headquartered in Horsham, United States, in the North America region.
Who are Palladio Biosciences's main competitors?
Direct peers on record are Otsuka Pharmaceutical, Reata Pharmaceuticals and XORTX Therapeutics. Broad incumbents are Galapagos NV, Vertex Pharmaceuticals and Sanofi. Eloxx Pharmaceuticals is listed as an emerging player.
Does Palladio Biosciences have an API?
No public API is recorded for Palladio Biosciences.
What industry is Palladio Biosciences in?
Palladio Biosciences's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 2834.